LivaNova Q2 revenue $352.5M (+10.7%), raises FY25 adjusted EPS guidance to $3.70-$3.80

LivaNova PLC

2025-Q2 EPS reported -$5.51 revenue$669,379,000

Revenue $352.5M, +10.7% reported, +10.3% organic; GAAP EPS $0.50, adjusted EPS $1.05.
Raised FY25 guidance: revenue growth 8-9% constant-currency, adj. EPS $3.70-$3.80 (midpoint +$0.10).
Adj. free cash flow $47.8M; FY25 raised to $140-160M.
Initiated CMS reconsideration for VNS Therapy for treatment-resistant depression based on RECOVER study.
Published 24-month CORE-VNS data showing VNS reduces generalized tonic-clonic seizures in DRE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.